Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970550 | 0.83 | CYP1A2 (0.35) | MEN1KMT2ACYP1B1GAAMAPT | |
| SCHEMBL3970556 | 0.80 | PGK1 (0.39) | MEN1KMT2AGAAMAPTPKM | |
| SCHEMBL3970549 | 0.80 | PGK1 (0.39) | MEN1KMT2AGAAMAPTPKM | |
| SCHEMBL6206210 | 0.78 | KDM4E (0.31) | MEN1KMT2A | |
| SCHEMBL3971037 | 0.66 | FGFR4 (0.38) | MEN1KMT2AMAPTRAB9AFGFR4 | |
| SCHEMBL3971035 | 0.66 | FGFR4 (0.38) | MEN1KMT2AMAPTRAB9AFGFR4 | |
| SCHEMBL3969852 | 0.65 | FGFR4 (0.34) | MEN1KMT2AMAPTRAB9AFGFR4 | |
| SCHEMBL3970879 | 0.63 | HTT (0.38) | MEN1KMT2AMAPT | |
| SCHEMBL23328260 | 0.62 | MEN1 (0.35) | MEN1KMT2AFGFR4 | |
| SCHEMBL21783949 | 0.62 | FGFR1 (0.47) | MEN1KMT2AFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | PDCD1 981/4885CD274 1518/4885MEN1 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.